Bringing the Patient Voice into Cancer Care and Research Ethan Basch, MD, MSc November 19, 2015.

Slides:



Advertisements
Similar presentations
Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.
Advertisements

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Depression in adults with a chronic physical health problem
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic)
AHRQ Annual Conference Patient-Reported Outcomes for Adverse Event Monitoring in Clinical Research Ethan Basch, M.D., M.Sc. Memorial Sloan-Kettering Cancer.
Methods used to assess and report pain-related endpoints in NDA Ethan Basch, MD, MSc Center for Drug Evaluation and Research.
ART-RIM Workshop National Cancer institute Ethan Basch, MD, MSc Memorial Sloan-Kettering Cancer Center Patient-reported Outcomes (PROs) January 22, 2010.
Is t he ‘Child’s Voice’ from Diagnosis to End-of-Life Trustworthy? Pamela S. Hinds, PhD, RN, FAAN Director, Department of Nursing Research and Quality.
Research Protocol ACRIN 6678 Learning About PET/CT Scans: Can PET/CT scans provide helpful information for the treatment of non-small cell lung cancer?
Wednesday, December 17, :00pm-4:30pm EST National Coalition for Cancer Survivorship Post-Training Webinar ©2014 National Coalition for Cancer Survivorship.
 Lowell Smith Sr. Director, Business & Communication Research Administration Moffitt Cancer Center  Jeanine Stiles Chief Administrative Officer Associate.
An overview of off-label drug use Ignoring the Label Samantha Rue.
Cancer Clinical Trials: The Way We Make Progress Against Cancer.
Myths and Facts About Cancer Clinical Trials. Copyright ENACCT, 2007 It’s a treatment of “last resort!” They treat you like a “guinea pig ” No one benefits.
PAIN ASSESSMENT PURPOSE  To provide guidelines for the appropriate identification and assessment of patients who may experience pain.
1  PI: Chih-Hung Chang, PhD  Grant #: 1R21CA  Project Period: 9/27/04-7/31/06  Program Official: Audie Atienza Novel Pain Assessment and Intervention.
How to Overcome Barriers and Develop Collaborative Guidelines Amir Qaseem, MD, PhD, MHA, FACP Chair, Guidelines International Network Director, Clinical.
NCI-sponsored treatment trials: CTCAE v4 790 individual items Standard Approach to AE Monitoring CATEGORYEXAMPLEDATA SOURCE LaboratoryNeutropeniaLaboratory.
1 Evidence and the next stage of health care reform: Why consumer engagement is so important Steven D. Pearson, MD, MSc President, Institute for Clinical.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic)
Community Oncology Conference Thursday April 23 rd, 2015.
A Comprehensive Approach to the Measurement of Health Outcomes Ron D. Hays, Ph.D. UCLA Department of Medicine November 25, 2008 K30 Track II Module Gonda.
FDA Approach to Review of Outcome Measures for Drug Approval and Labeling: Content Validity Initiative on Methods, Measurement, and Pain Assessment in.
It Is Time for Self-Incident-Reporting for Patients and Their Families in Every Health Care Organization: A Literature Review Medinfo 2013, Paper Session:
Quentin R. Burdick Grant Interdisciplinary Learning in Rural Healthcare at East Tennessee State University East Tennessee State University.
Palliative Care Across the Continuum of Illness Jean Endryck, FNP-BC, ACHPN, NE-BC Director of Palliative Care St. Peter’s Health Partners/Seton Health.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
Immunotherapy Sara Engh & Tenzin Yiga. Role of the Immune system ➔ Defends against pathogens such as bacteria, fungi, and viruses that enter the body.
Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility)
AcademyHealth 2007 Gender Differences in Healthcare Utilization at the End-of Life Andrea Kronman, MD MSc Boston University BIRCWH Faculty Scholar Women’s.
Consent for Research Study A study using 18 F-Fluoride for prostate cancer patients currently enrolled in Dr. Febbo’s “Genomic Guided Therapy” study A.
Randy A. Jones, PhD, RN Patricia Hollen, PhD, RN, FAAN Richard Steeves, PhD, RN, FAAN Terran Sims, MSN, RN, ACNP-BC Christopher Thomas, MD University of.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Interdisciplinary Clinical Student Training in Teamwork and Geriatric Assessment: A Student Pharmacist’s Perspective Presented by: Catherine Liu, PharmD.
Geriatric Oncology: Breast Cancer UNC Lineberger: Cancer and Older Adults November 19, 2015 Hyman B. Muss, MD.
Health-related quality of life in patients with oesophageal- and gastric cancer Lovisa Backemar, MD Surgical Care Sciences Department of Molecular Medicine.
Sandra A. Mitchell, PhD, CRNP Outcomes Research Branch, DCCPS
Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
A Holistic Approach To Discharge Planning. Due to the regulatory guidelines and changes in healthcare for example: Bounce backs Reduced hospitalizations.
Reader’s Digest Introduction to Health-Related Quality of Life Ron D. Hays, Ph.D. UCLA Department of Medicine April 25, 2008 (Signature Grand) Nova Southeastern.
No Conflicts of Interest Including the Patient Voice in Safety Reporting Ethan Basch, MD, MSc Health Outcomes Group Departments of Medicine and Epidemiology/Biostatistics.
NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Symptom Benefit Study Measuring the Benefit of Palliative Chemotherapy.
Standards and Competencies for Cancer Chemotherapy Nursing Practice in Canada: CANO/ACIO AN INTRODUCTION.
A Multidisciplinary Leadership Model in a Community Health Center Greg Thesing, MD November 2014.
Clinical trials in the Elderly What are we missing? Jan C. Buckner, MD Chicago, IL May, 2015.
CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?
The Influence of Comorbidities on Use of Symptom Management Strategies in a Cancer Patient Intervention Gerontological Society of America November 19,
Breast Cancer Treatment. Treatment 2 aspects 1. Treatment of the breast itself: “Local Treatment” 2. Treatment of the whole body = “Systemic treatment”
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Danielle Lavallee, PharmD, PhD Department of Surgery
CIPN: Considerations for Drug Development
Medication Adherence: The Quality Bullet
Quality of Life Assessment
Implementation of Project: Nursing Role/Responsibilities:
Cancer & Aging Research Group (CARG)
Department of Emergency Medicine Kevin Biese, MD, MAT
What Are Clinical Trials?
Learning About PET/CT Scans:
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Survivorship Pathway Template
Nicholas D Hartman, M. D. , M. P. H. 1, Kim L. Askew, M. D. 1, David E
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Comparison of Seven-Day and Repeated 24-Hour Recall of Symptoms in the First 100 Days After Hematopoietic Cell Transplantation  William A. Wood, MD, MPH,
Collaborative Learning Workshops to Optimize Integration of Cancer
Living with Ovarian Cancer: How Palliative Care Can Help
Presentation transcript:

Bringing the Patient Voice into Cancer Care and Research Ethan Basch, MD, MSc November 19, 2015

Symptoms Common and often debilitating in cancer Recognizing symptoms is a key role of doctors and nurses – During cancer treatment – In clinical trials

Symptoms Often Go Undetected Up to half of patients’ symptoms are missed during cancer treatment Nausea Fatigue Months Anorexia Vomiting Months Patient- reported Clinician- reported 3

Serious Implications Under-management of symptoms during cancer treatment Under-documentation of symptoms and side effects in clinical trials

Research on “Patient-Reported Outcomes” Develop questionnaires and software to enable patient self-reporting of symptoms, physical functioning and “quality of life” Test these approaches during routine chemotherapy care and in clinical trials nationally Work closely with NCI, FDA, pharmaceutical industry, etc.

UNC is a National Leader in this Area Angie Smith, MD Arlene Chung, MD Bryce Reeve, PhD Antonia Bennett, PhD Bill Wood, MD Hy Muss, MD Grant Williams, MD

Examples

Pain Common in cancer, not well controlled – Reported by 2/3 patients with advanced disease Inadequate analgesics among 1/3

Particularly True in Prostate Cancer More than half with advanced disease report clinically meaningful pain (>4 on 0-10 NRS)

1996 Approved based on an old patient pain questionnaire

Only 1 other oncology drug approved by FDA based on patient-reported information (Ruxolitinib, 2011) Surprising, given how common symptoms and functional impairment are in oncology

FDA introduced a “PRO Guidance” Outlined standards - Patient interviews - Testing - Relevance to trials - Implementation, analysis Groundbreaking… but overly stringent, and industry was largely unwilling and unable to adhere in most cases Why So Rare? U.S. Food & Drug Administration

Researcher Role Worked with FDA on approach to PROs in oncology – Outcome: pain intensity – Measure: 0-10 NRS (BPI) – Recall: 24 hours – Meaningful change: 30% or 2 points – Analgesic use: integrated into design – Analysis approaches

Work with Industry

Work with Consensus Groups

Work with National Clinical Practice Guidelines

A Second Example Measuring symptom side effects in clinical trials – Clinicians miss many of these – UNC researchers led development of approach for patients to report their own side effects Developed for the National Cancer Institute Called the “PRO-CTCAE”

Developed/Tested Questionnaire and Software

Clinician Reporting Patient Reporting Shows Better Symptom Detection in Trials

Improves Outcomes during Treatment Improved QOL, longer chemotherapy, fewer ER visits

Recent Publications on PRO-CTCAE

Support PRO Software for Many Trials UNC Cancer Center “PRO-Core"

Patient-Centered Approaches to Quality of Care Standards for Patient- Reported Outcome-based Performance Measures

PROs in Geriatrics Key to measure the patient experience – risk of comorbidities; functional impairments – E.g., the GA Older patients are enthusiastic to self-report Enables communication Methods research considerations – What outcomes, how ask questions, how often, how use the information, how report results? – Requires interdisciplinary collaboration

Thank You